Sözen T, Özışık L, Başaran NÇ (2016) An overview and management of osteoporosis. Eur J Rheumatol 4:46

Article  PubMed  PubMed Central  Google Scholar 

Russell RGG (2011) Bisphosphonates: the first 40 years. Bone 49:2–19

Article  CAS  PubMed  Google Scholar 

Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105:587–594

Article  Google Scholar 

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

Article  CAS  PubMed  Google Scholar 

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543

Article  CAS  PubMed  Google Scholar 

Diez-Perez A, Adachi J, Agnusdei D, Bilezikian J, Compston J, Cummings S, Eastell R, Eriksen E, Gonzalez-Macias J, Liberman U (2012) Treatment failure in osteoporosis. Osteoporos Int 23:2769–2774

Article  CAS  PubMed  Google Scholar 

Kim S, Lee D (2023) A retrospective analysis of nonresponse to denosumab after hip fractures. Acta Orthop Belg 89:71–76

Article  CAS  PubMed  Google Scholar 

Anna G, Anne-Lise F, Clemence D, Jean-Michel P, Florence T (2023) Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis. J Bone Miner Metab 41:278–285. https://doi.org/10.1007/s00774-023-01412-3

Article  CAS  PubMed  Google Scholar 

Delmas P, Eastell R, Garnero P, Seibel M, Stepan J, CoSAotIO F (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11:S2

Article  PubMed  Google Scholar 

Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2016) A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int 27:2845–2853

Article  CAS  PubMed  Google Scholar 

Miller P, Hattersley G, Lau E, Fitzpatrick L, Harris A, Williams G, Hu M-Y, Riis B, Russo L, Christiansen C (2019) Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial. Bone 120:137–140

Article  CAS  PubMed  Google Scholar 

Gallagher JC, Rosen C, Chen P, Misurski D, Marcus R (2006) Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 39:1268–1275

Article  CAS  PubMed  Google Scholar 

Sebba AI (2008) Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clin Ther 30:443–452

Article  CAS  PubMed  Google Scholar 

Ramchand SK, David NL, Leder BZ, Tsai JN (2020) Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT. J Clin Endocrinol Metab 105:890–897

Article  PubMed  Google Scholar 

Powell DE, Evans SF, Rakieh C (2023) Bone mineral density response to long-term bisphosphonate treatment and discontinuation in a real-world clinical service. Endocr Pract 29:601–605. https://doi.org/10.1016/j.eprac.2023.04.011

Article  PubMed  Google Scholar 

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427

Article  CAS  PubMed  Google Scholar 

McClung MR, Betah D, Leder BZ, Kendler DL, Oates M, Timoshanko J, Wang Z (2025) Romosozumab improves microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis. J Bone Miner Res 40:193–200

Article  PubMed  Google Scholar 

Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

Article  CAS  PubMed  Google Scholar 

Mawatari T, Ikemura S, Matsui G, Iguchi T, Mitsuyasu H, Kawahara S, Maehara M, Muraoka R, Iwamoto Y, Nakashima Y (2020) Assessment of baseline bone turnover marker levels and response to risedronate treatment: data from a Japanese phase III trial. Bone Rep 12:100275. https://doi.org/10.1016/j.bonr.2020.100275

Article  PubMed  PubMed Central  Google Scholar 

Vasikaran SD, Miura M, Pikner R, Bhattoa HP, Cavalier E, Metabolism I-IJCoB (2023) Practical considerations for the clinical application of bone turnover markers in osteoporosis. Calcif Tissue Int 112:148–157

Article  CAS  PubMed  Google Scholar 

Bhattoa HP, Vasikaran S, Trifonidi I, Kapoula G, Lombardi G, Jørgensen NR, Pikner R, Miura M, Chapurlat R, Hiligsmann M (2025) Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos Int. https://doi.org/10.1007/s00198-025-07422-3

Article  PubMed  PubMed Central  Google Scholar 

Schini M, Vilaca T, Gossiel F, Salam S, Eastell R (2023) Bone turnover markers: basic biology to clinical applications. Endocr Rev 44:417–473

Article  PubMed  Google Scholar 

Hattori K, Kanayama Y (2024) Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab. Mod Rheumatol 34:1047–1055

Article  CAS  PubMed  Google Scholar 

Seguro L, Casella C, Caparbo V, Oliveira R, Bonfa A, Bonfa E, Pereira R (2015) Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients. Osteoporos Int 26:459–467

Article  CAS  PubMed  Google Scholar 

Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364–376. https://doi.org/10.1016/S0140-6736(18)32112-3

Article  CAS  PubMed  Google Scholar 

Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A (2018) Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 14:576–590.

Schini M, Vilaca T, Lui LY, Ewing SK, Thompson A, Vittinghoff E, Bauer DC, Bouxsein ML, Black DM, Eastell R (2024) Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project. J Bone Miner Res 39:867–876. https://doi.org/10.1093/jbmr/zjae068

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients: response to comments. Osteoporos Int 28:1757–1758. https://doi.org/10.1007/s00198-017-3923-5

Article  CAS  PubMed  Google Scholar 

Pinkerton JV, Thomas S (2014) Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol 142:142–154

Article  CAS  PubMed  Google Scholar 

Ramchand SK, Leder BZ (2024) Sequential therapy for the long-term treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 109:303–311

Article  CAS  PubMed  Google Scholar 

Langdahl B (2020) Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone 139:115516

Article  CAS